United Therapeutics Corp (UTHR) Files Form 4 Insider Selling : Martine A Rothblatt Sells 5,547 Shares

United Therapeutics Corp (UTHR): Martine A Rothblatt , Chairman & Co-CEO of United Therapeutics Corp sold 5,547 shares on May 26, 2016. The Insider selling transaction was reported by the company on May 31, 2016 to the Securities and Exchange Commission. The shares were sold at $117.86 per share for a total value of $652,146.38 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 20, 2016, Martine A Rothblatt (Chairman & Co-CEO) sold 5,546 shares at $111.71 per share price.On May 13, 2016, Raymond Dwek (director) sold 3,000 shares at $110.00 per share price.Also, On Mar 3, 2016, Tommy G Thompson (director) sold 3,000 shares at $126.54 per share price.On Nov 4, 2015, Richard Giltner (director) sold 7,500 shares at $153.22 per share price.

United Therapeutics Corporation: On Friday, May 27, 2016 heightened volatility was witnessed in United Therapeutics Corporation which led to swings in the share price. The shares opened for trading at $116.98 and hit $117.89 on the upside , eventually ending the session at $117.78, with a gain of 0.54% or 0.63 points. The heightened volatility saw the trading volume jump to 4,06,275 shares. The 52-week high of the share price is $190.13 and the company has a market cap of $5,256 M . The 52-week low of the share price is at $102.5.

United Therapeutics Corporation Money Flow Index Chart

Company has been under the radar of several Street Analysts.United Therapeutics Corporation is Downgraded by Ladenburg Thalmann to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Apr 29, 2016.United Therapeutics Corporation is Reiterated by RBC Capital Mkts to Sector Perform while Lowering the Price Target of the company shares to $ 122 from a previous price target of $150 . The Rating was issued on Apr 11, 2016.United Therapeutics Corporation is Reiterated by Wedbush to Outperform while Lowering the Price Target of the company shares to $ 229 from a previous price target of $238 . The Rating was issued on Mar 28, 2016.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company’s key therapeutic products and product candidates include Remodulin Tyvaso (treprostinil) Adcirca (tadalafil) Remodulin Implantable System Orenitram Combination Therapy Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation for the treatment of End-stage lung disease; UV-4B for the treatment of Dengue and influenza and Glycobiology Antiviral Agents for the treatment of a spectrum of agents against viral infectious diseases among others. The Company’s lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.

Leave a Reply

United Therapeutics Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on United Therapeutics Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.